Assessment of our registered patients’ eligibility for Phase III trials of DOACs
We scrutinised the most frequently used inclusion and exclusion criteria of the four DOACs Phase III trials (Table 1).1,2,4,5Baseline data collected at registration for all patients (medical history, background, and laboratory values) were checked against the developed inclusion and exclusion criteria to assess eligibility. Regarding the CHADS2 score, two trials used ≥2 as a criterion, and the others used ≥1. We used ≥2 as our criterion. Therefore, ineligible patients included those with a CHADS2 score of <2. In addition, we checked the baseline data against each Phase III trial’s inclusion and exclusion criteria.